Hepatitis virus-like particles as potential cancer treatment
UC Davis researchers have developed a way to use the empty shell of a hepatitis E virus to carry vaccines or drugs into the body. The technique has been tested in rodents as a way to target breast cancer, and is available for commercial licensing through UC Davis Office of Research.
Hepatitis E virus capsids can resist passing through the digestive system. These virus-like particles could be used to carry vaccines or drugs into the body through the oral route. By modifying the capsid proteins, UC Davis researchers show that they can attach molecules to the particle surface that target breast cancer cells.
Marie Stark/UC Davis
Hepatitis E virus is feco-orally transmitted, so it can survive passing through the digestive system, said Marie Stark, a graduate student working with Professor Holland Cheng in the UC Davis Department of Molecular and Cell Biology.
Cheng, Stark and colleagues prepared virus-like particles based on Hepatitis E proteins. The particles do not contain any virus DNA, so they can't multiply and spread and cause infections.
Such particles could be used as vaccines that are delivered through food or drink. The idea is that you would drink the vaccine, and after passing through the stomach the virus-like particles would get absorbed in the intestine and deliver vaccines to the body.
But the particles could also be used to attack cancer. Stark and Cheng did some tinkering with the proteins, so that they carry sticky cysteine amino acids on the outside. They could then chemically link other molecules to these cysteine groups.
They worked with a molecule called LXY-30, developed by researchers at the UC Davis Comprehensive Cancer Center, which is known to stick to breast cancer cells. By using a fluorescent marker, they could show that virus-like particles carrying LXY-30 could home in on breast cancer cells both in a laboratory dish and in a mouse model of breast cancer.
So perhaps one day, cancer patients might drink their medicine and UC Davis-designed virus-like particles carrying anticancer drugs will home in on their target.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
